Immunogenicity comparison of conjugate vaccines composed of alginate and lipopolysaccharide of Pseudomonas aeruginosa bound to diphtheria toxoid
-
Faezeh Najafzadeh
,
Ghazaleh Jaberi
,
Reza Shapouri
,
Mehdi Rahnema
,
Ashraf Karimi-Nik
,
Anvarsadat Kianmehr
Abstract
Background and Objectives: Treatment of Pseudomonas aeruginosa infections is greatly hampered by innate and acquired antibiotic resistance. The goal of this study was to compure the immunogenicity of conjugates of P. aeruginosa depolymerized alginate-diphtheria toxoid (D-ALGDT) and P. aeruginosa detoxified lipopolysaccharidediphtheria toxoid (D-LPSDT) in mouse model.
Materials and Methods: Alginate and LPS were purified from P. aeruginosa strain PAO1. The resulting depolymerized alginate (D-ALG) and detoxified LPS (D-LPS) were covalently coupled to diphtheria toxoid (DT) as a carrier protein with adipic acid dihydrazide (ADH) as a spacer molecule and carbodiimide as a linker. Sterility, safety and pyrogenicity tests were performed. 30 mice in two groups were immunized intraperitoneally on days 0, 14 and 28 with 10 µg of D-ALGDT and D-LPSDT. Conjugates specific antibody levels were also determined by enzyme-linked immunosorbent assay (ELISA).
Results: The conjugates were non-toxic and non-pyrogenic. Conjugates of D-ALGDT and D-LPSDT were shown to be safe and to elicit total IgG, IgM, IgA, IgG1, IgG2a, IgG2b and IgG3 antibodies in mice. ELISA results indicated that antibodies titer of D-ALGDT was more than D-LPSDT.
Conclusion: Immunization with D-ALGDT showed significant increase in all types of antibodies titers in versus D-LPSDT,suggesting D-ALGDT as a vaccine candidate against P. aeruginosa infections.
Peluso L, de Luca C, Bozza S, Leonardi A, Giovannini G, Lavorgna A, et al. Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization. BMC Microbiol 2010; 10: 1-11.
Stanislavsky ES, Lam JS. Pseudomonas aeruginosa antigens as potential vaccines. FEMS Microbiol Rev 1997; 21: 243-277.
Priebe GP, Pier GB (2003). Vaccines for Pseudomonas aeruginosa. In: New Bacterial Vaccines. Ed, RW Ellis, BR Brodeur. Plenum Publishing, 1st ed. pp. 260-282.
Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Human Vaccines 2011; 7:999-1011.
Japoni A, Farshad S, Alborzi A. Pseudomonas aeruginosa: burn infection, treatment and antibacterial resistance. Iran Red Crescent Med J 2009; 11:244-253.
Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydrate Research 2003; 338: 2539-2547.
Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Médecine et Maladies Infectieuses 2006; 36: 78-91.
Holder IA. Pseudomonas immunotherapy: a historical overview. Vaccine 2004; 22: 831-839.
Kashef N, Behzadian-Nejad Q, Najar-Peerayeh S, Mousavi-Hosseini K, Moazzeni M, Esmaeeli Djavid G. Synthesis and characterization of Pseudomonas aeruginosa alginate–tetanus toxoid conjugate. J Med Microbiol 2006; 55: 1441-1446.
Al-Zeer M, Masoud H. LPS-based conjugate vaccines composed of O-polysaccharide from Pseudomonas aeruginosa IATS 6 and 11 bound to a carrier protein. World J Microbiol Biotechnol 2007; 23:1541-1549.
Aspe M, Jensen L, Melegrito J, Sun M. The role of alginate and extracellular DNA in biofilm-meditated Pseudomonas aeruginosa gentamicin resistance. J Exp Microbiol Immunol 2012; 16: 42-48.
Kashef N, Behzadian-Nejad Q, Najar-Peerayen S, Mousavi-Hosseini K, Moazeni M, Rezvan H, Adibi- motlagh B. Preliminary investigation on the isolation of alginate produced by mucoid Pseudomonas aeruginosa. Ann Microbiol 2005; 55: 279-282.
Said AA, Livermore DM, Williams RJ. Expression of H 1 outer-membrane protein of Pseudornonas aeruginosa in relation to sensitivity to EDTA and polymyxin B. J Med Microbiol 1987; 24: 267-274.
Rezania S, Amirmozaffari N, Tabarraei B, Jeddi- Tehrani M, Zarei O, Alizadeh R, et al. Extraction, purification and characterization of lipopolysaccharide from Escherichia coli and Salmonella typhi. Avicenna J Med Biotech 2011; 3: 3-9.
Shapouri R, Mohabati Mobarez A, Ahmadi H, Tabaraie B, Hosseini Doust R, Norozian D, et al. Optimization of Brucella abortus fermenter cultural conditions and LPS extraction method for antigen production. Res J Microbiol 2008; 3: 1-8.
Sharifat Salmani A, Siadat SD, Norouzian D, Ahmadi H, Nejati M, Tabaraie B, et al. Optimization of Brucella abortus S99 lipopolysaccharide extraction by phenol and butanol methods. Res J Biol Sci 2008; 3: 576-580.
Renukadevi KP, Angayarkanni J, Karunakaran G.Extraction and characterization of lipopolysaccharide from Serratia rubidaea and its cytotoxicity on lung cancer cell line - NCI-H69. Acta Technica Corvininesis - Bulletin of Engineering 2012; 5: 97-101.
Konadu E, Robbins JB, Shiloach J, Bryla DA, Szu SC. Preparation, characterization, and immunological roperties in mice of Escherichia coli 0157 0-specific polysaccharide-protein conjugate vaccines. Infect Immun 1994; 62: 5048-5054.
Hudson L, Hay FC (1989). Practical immunology. 3th ed. Blackwell Science pub.20. Cryz SJ JR, Fürer E, Que JU. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infection and Immunity 1991; 59: 45-50.
Seid RC Jr, Sadoff JC. Preparation and characterization of detoxified lipopolysaccharide-protein conjugates. J Biol Chem 1981; 256: 7305-7310.
Kabir S. Preparation and immunogenicity of a bivalent cell-surface protein-polysaccharide conjugate of Vibrio cholerae. J Med Microbiol 1987; 23: 9-18.
Watson DC, Robbins JB, Szu SC. Protection of mice against Salmonella typhimunium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun 1992; 60: 4679-4686.
Goldstein J, Hoffman T, Frasch C, Lizzio EF, Beining PR, Hochstein D, et al. Lipopolysaccharide (LPS) from Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vaccines. Infect Immun 1992; 60: 1385-1389.
Cryz SJ Jr, Sadoff JC, Fürer E, Germanier R.Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans. J Infect Dis 1986; 154: 682-688.
Midwinter A, Faine S, Adler B. Vaccination of mice with lipopolysaccharide (LPS) and LPS-derived immuno-conjugates from Leptospira interrogans. J Med Microbiol 1990; 33: 199-204.
Cryz SJ JR, Fürer E, Cross AS, Wegmann A, Germanier R, Sadoff JC. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest 1987; 80: 51-56.
Kossaczka Z, Shiloach J, Johnson V, Taylor DN, Finkelstein RA, Robbins JB, et al. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect Immun 2000; 68: 5037-5043.
Chu C, Liu B, Watson D, Szu S, Bryla D, Shiloach J, et al.Preparation, characterization, and mmunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga’s bacillus) bound to tetanus toxoid. Infect Immun 1991; 59: 4450-4458.
Gupta RK, Egan W, Bryla DA, Robbins JB, Szu SC.Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes. Infect Immun 1995; 63: 2805-2810.
Gupta RK, Szu SC, Finkelistein RA, Robbins JB.Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae 01 serotype Inaba bound to cholera toxin. Infect Immun 1992; 60:3201-3208.
Pier GB. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. Int J Med Microbiol 2007; 297: 277-295.
Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007; 13: 560-578.
| Files | ||
| Issue | Vol 6 No 5 (2014) | |
| Section | Articles | |
| Keywords | ||
| Pseudomonas aeruginosa alginate (ALG) conjugate vaccine diphtheria toxoid (DT) lipopolysaccharide (LPS) | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
